Trial · NCT07891936
Creatine and Muscle Health in Madrid's Walking Footballers.
NCT07891936, Not applicable, Not yet recruiting, Universidad Europea de Madrid
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Creatine and Muscle Health in Madrid's Walking Footballers. Trials, record NCT07891936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891936
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Creatine and Muscle Health in Madrid's Walking Footballers.
- NCT number
- NCT07891936
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Universidad Europea de Madrid
- Conditions
- Muscle Adaptation, Body Composition, Physical Activity in Adults
- Interventions
- Monohydrate Creatine supplementation during Walking Football training
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes67
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Muscle Quality | From enrollment to the end of treatment at 32 weeks | It is defined as the capacity of skeletal muscle to generate strength relative to its mass, integrating both structural and functional aspects. It will be expressed as the ratio between the estimated 1-RM strength and muscle mass measured by dual-energy X-ray absorptiometry (DEXA) |
| Secondary | Nutritional profile | From enrollment to the end of treatment at 32 weeks | This will be assessed through a nutritional interview conducted by a professional, which will include a complete dietary history, a 24-hour dietary recall (24hR), and a food frequency questionnaire (FFQ) |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | assessed through basic anthropometry: weight in kilogram (kg) |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | assessed through basic anthropometry: height in centimeter (cm) |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | assessed through basic anthropometry: body mass index (BMI), weight and height will be combined to report BMI in kg/m\^2 |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | Dual X-Ray Densitometry: body adiposity index, (BAI) in perctange (%) |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | Dual X-Ray Densitometry: fat mass index (FMI) kilograms per square meter. kg/m² |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | Dual X-Ray Densitometry: visceral adipose tissue area, VAT Area in square centimeter (cm²) |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | Dual X-Ray Densitometry: skeletal muscle mass index, (SMI) kilograms per square meter. kg/m² |
| Secondary | Body composition | From enrollment to the end of treatment at 32 weeks | Dual X-Ray Densitometry: appendicular skeletal muscle mass index, (ASM). kilograms per square meter. kg/m² |
1 to 10 of 67Source ClinicalTrials.gov
See all 67 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891936
GET https://conductscience.org/api/trials/v1/NCT07891936/registered?page=2